Skip to main content

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

Medically reviewed by Carmen Pope, BPharm. Last updated on July 2, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases detection of new cognitive conditions/concerns in older adults, according to a study published online June 12 in Frontiers in Medicine.

Douglas W. Scharre, M.D., from The Ohio State University Wexner Medical Center in Columbus, and colleagues compared PCP visits with and without using the self-administered SAGE to determine differences in identification rates of new cognitive disorders. The analysis included 300 patients (aged 65 to 89 years) without diagnosed cognitive disorders completing a nonacute office visit.

The researchers found that when SAGE was utilized, the PCP documented the detection of new cognitive conditions/concerns six times as often (9 versus 1.5 percent). For those with cognitively impaired SAGE scores, the detection rate was nearly fourfold higher, while patients having impaired SAGE score and informant concerns were 15-fold as likely to have new cognitive conditions/concerns documented.

"PCPs felt SAGE influenced their decision to further evaluate for cognitive impairment, led to more confidence regarding the presence or absence of cognitive impairment, and 86 percent would recommend its use to colleagues," the authors write.

The Ohio State University holds the copyright for the SAGE test. One author disclosed ties to BrainTest.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Membranous Labyrinth Distension Seen in MRI of Meniere Disease

TUESDAY, July 2, 2024 -- Distension of the membranous labyrinth is seen in histologic specimens from deceased patients with symptoms consistent with Meniere disease and in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.